体外膜氧合并发症并非梗死相关心源性休克患者死亡的因果原因:ECLS-SHOCK试验的中介分析
该研究为ECLS-SHOCK随机试验的子分析,纳入417例急性心肌梗死合并心源性休克(AMI-CS)成人患者,比较常规VA-ECMO支持与单纯药物治疗。VA-ECMO组中重度出血(23.4% vs 9.6%,p<0.001)和需干预的外周血管并发症(11.0% vs 3.8%,p=0.008)均高于对照组,仅4例以出血为主要死因。因果中介分析显示可能的VA-ECMO相关并发症对30天死亡率无显著中介效应,逻辑回归亦未发现其与死亡率显著相关。
要点
- 在AMI-CS患者中,VA-ECMO组中重度出血发生率23.4%(49例)高于对照组9.6%(20例),p<0.001。
- VA-ECMO组需干预的外周血管并发症发生率11.0%(23例)高于对照组3.8%(8例),p=0.008。
- 可能的VA-ECMO相关并发症多发生在随机化后5天内。
- 仅4例患者以出血为主要死因。
- 因果中介分析显示可能的VA-ECMO相关并发症对30天死亡率无显著中介效应。
适用人群与场景
- 急性心肌梗死合并心源性休克(AMI-CS)的成人患者。
研究设计与关键结果
- 研究类型:ECLS-SHOCK随机对照试验的子分析,国际多中心,共44个中心。
- 样本量:纳入417例患者。
- 干预与对照:常规VA-ECMO支持 vs 单纯药物治疗。
- 主要终点结果:可能的VA-ECMO相关并发症(中重度出血及需干预的外周血管并发症)发生率VA-ECMO组23.4%(49例)vs 对照组9.6%(20例),p<0.001(出血);外周血管并发症VA-ECMO组11.0%(23例)vs 对照组3.8%(8例),p=0.008。
- 仅4例患者以出血为主要死因。
- 因果中介分析:可能的VA-ECMO相关并发症对30天死亡率无显著中介效应。
- 逻辑回归分析:VA-ECMO相关并发症频率与死亡率无显著关联。
证据类型、等级与局限
- 证据类型:随机对照试验(ECLS-SHOCK)的子分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在AMI-CS患者中,常规VA-ECMO支持与中重度出血及需干预的外周血管并发症频率增加相关,但这些并发症未中介增加死亡风险。
指南或共识出处
- ECLS-SHOCK试验(Extracorporeal Life Support in Infarct-Related Cardiogenic Shock),ClinicalTrials.gov注册号NCT03637205,注册日期2018年8月。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Recently published randomized controlled trials and an individual patient data meta-analysis showed that the routine use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) did not reduce mortality compared with medical therapy alone in patients with acute myocardial infarction complicated by cardiogenic shock (AMI-CS). The objective of this study was to investigate whether possible VA-ECMO-related medical complications are associated with increased mortality risk, which might explain the observed equipoise among mortality outcomes between VA-ECMO and usual care.
DESIGN: Sub-analysis of the randomized Extracorporeal Life Support in Infarct-Related Cardiogenic Shock (ECLS-SHOCK) trial.
SETTING: Multicenter, international randomized controlled trial across 44 centers specialized in treating AMI-CS.
PATIENTS: Adults patients with AMI-CS.
INTERVENTIONS: Patients received either routine VA-ECMO support or medical therapy.
MEASUREMENTS AND MAIN RESULTS: The rate of complications and mortality as well as causes of death within 30 days. In total, 417 patients were included in this analysis. Moderate and severe bleeding as well as peripheral vascular complications requiring intervention were classified as possible VA-ECMO-related complications. A total of 88 patients (21.1%) developed possible VA-ECMO-related complications, which mostly occurred within five days after randomization and more frequently in the VA-ECMO group than in the control group: 49 (23.4%) vs. 20 (9.6%) patients, p < 0.001 for bleeding and 23 (11.0%) vs. 8 (3.8%) patients, p equals to 0.008 for peripheral vascular complications, respectively. Only four patients died from bleeding as the primary cause of death. Causal mediation analyses revealed no significant mediation effect of possible VA-ECMO-related complications on 30-day mortality. Logistic regression analyses of possible VA-ECMO-related complications confirmed no significant associations between the frequency of VA-ECMO-related complications and mortality.
CONCLUSIONS: VA-ECMO use in patients with AMI-CS was associated with increased frequencies of moderate to severe bleeding as well as vascular complications warranting intervention. However, these possible VA-ECMO-related complications did not mediate an increased mortality risk.
TRIAL REGISTRATION: ClinicalTrials.gov , protocol: NCT03637205; August 2018.
参考来源
- Thevathasan T, Alyahoud M, Freund A, et al. Extracorporeal Membrane Oxygenation Complications Are Not Causal for Mortality in Patients With Infarct-Related Cardiogenic Shock: A Mediation Analysis of the Extracorporeal Life Support in Infarct-Related Cardiogenic Shock (ECLS-SHOCK) Trial. Crit Care Med. 2025. PMID: 41114622. doi:10.1097/CCM.0000000000006893
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。